Articles with public access mandates - Yifei WangLearn more
Not available anywhere: 1
Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium
P Hingorani, W Zhang, Z Zhang, Z Xu, WL Wang, ME Roth, Y Wang, ...
Molecular cancer therapeutics 21 (8), 1318-1325, 2022
Mandates: US National Institutes of Health
Available somewhere: 6
The B7-H3–targeting antibody–drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models
NM Kendsersky, J Lindsay, EA Kolb, MA Smith, BA Teicher, SW Erickson, ...
Clinical Cancer Research 27 (10), 2938-2946, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
What are the conditional survival and functional outcomes after surgical treatment of 115 patients with sacral chordoma?
T Ji, W Guo, R Yang, X Tang, Y Wang, L Huang
Clinical Orthopaedics and Related Research® 475 (3), 620-630, 2017
Mandates: National Natural Science Foundation of China
En bloc resection of pelvic sarcomas with sacral invasion: a classification of surgical approaches and outcomes
Y Zhang, W Guo, X Tang, R Yang, T Ji, Y Yang, Y Wang, R Wei
The bone & joint journal 100 (6), 798-805, 2018
Mandates: National Natural Science Foundation of China
ABBV-085, antibody–drug conjugate targeting LRRC15, is effective in osteosarcoma: a report by the pediatric preclinical testing consortium
P Hingorani, ME Roth, Y Wang, W Zhang, JB Gill, DJ Harrison, B Teicher, ...
Molecular cancer therapeutics 20 (3), 535-540, 2021
Mandates: US National Institutes of Health
Combining of serial embolization and denosumab for large sacropelvic giant cell tumor: case report of 3 cases
T Ji, Y Yang, Y Wang, K Sun, W Guo
Medicine 96 (33), e7799, 2017
Mandates: National Natural Science Foundation of China
Comprehensive surfaceome profiling to identify and validate novel cell-surface targets in osteosarcoma
Y Wang, X Tian, W Zhang, Z Zhang, R Lazcano, P Hingorani, ME Roth, ...
Molecular cancer therapeutics 21 (6), 903-913, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Publication and funding information is determined automatically by a computer program